Q: What is Amvuttra?

Amvuttra belongs to a class of medications known as RNA interference (RNAi) therapeutics . It works by targeting and breaking down the specific messenger RNA needed to produce the transthyretin protein in the liver. By interfering with this genetic process, the medication lowers the levels of transthyretin protein circulating in the blood. This reduction is the primary mechanism by which the therapy functions within the body.

Q: What is Amvuttra used for?

Amvuttra is used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Q: How does Amvuttra work?

Mechanism of Action Amvuttra is a type of medicine called a small interfering ribonucleic acid (siRNA). It is designed to target and reduce the levels of a protein called transthyretin (TTR), which is mostly produced in the liver. In patients with hereditary transthyretin-mediated (hATTR) amyloidosis, the body produces abnormal TTR proteins. These proteins can misfold and stick together, forming deposits known as amyloid. These deposits build up in various parts of the body, including the nerves, leading to symptoms like numbness, pain, and weakness (polyneuropathy). How it Works in the Body Amvuttra works through a biological process called RNA interference. It identifies and breaks down the messenger RNA (mRNA) that provides the instructions for making the TTR protein. By blocking these instructions, the medication significantly lowers the amount of TTR protein released into the blood. By decreasing the levels of this protein, Amvuttra helps to: Limit the further buildup of amyloid deposits in the tissues. Slow the progression of nerve damage associated with the condition.

Q: What are the active ingredients in Amvuttra?

The active ingredient in Amvuttra is vutrisiran .

Q: What are the side effects of Amvuttra?

Common side effects of Amvuttra may include: injection site reactions arthralgia nausea Always consult with a healthcare professional about potential side effects.

Q: What drug class is Amvuttra?

Amvuttra belongs to the RNA interference therapeutic drug class.

Q: What is the dosage of Amvuttra and how do I take it?

Administration Amvuttra is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. A healthcare professional will perform the injection in a clinical setting. Common injection sites include: The abdomen The thighs The back of the upper arms Dosing Schedule This medication is typically scheduled for administration once every three months. It is important to keep all scheduled appointments to ensure the medication works effectively. Missed Doses If a dose is missed, the injection should be administered by a healthcare professional as soon as possible. After receiving the missed dose, the next injection should be scheduled for three months after that date to maintain the regular quarterly cycle. Vitamin A Supplementation Because this medication can lower the levels of vitamin A in the blood, healthcare providers generally recommend taking a daily vitamin A supplement while receiving treatment. Patients should follow their provider's specific instructions regarding the amount and type of supplement to use.

Q: Is Amvuttra safe during pregnancy and breastfeeding?

Pregnancy There are no adequate and well-controlled studies of Amvuttra in pregnant individuals. Because the medication reduces the levels of transthyretin protein in the blood, it also leads to a significant decrease in serum vitamin A levels. Vitamin A is necessary for the normal development of a fetus. In animal studies, vutrisiran showed evidence of developmental toxicity when administered at doses that were also toxic to the mother. While patients taking Amvuttra are typically advised to take vitamin A supplements, both vitamin A deficiency and excessive vitamin A intake can be harmful during pregnancy. Individuals who are pregnant or planning to become pregnant should discuss the potential risks and benefits of treatment with their healthcare provider. Breastfeeding It is not known if Amvuttra is present in human breast milk, nor is it known how the drug might affect a nursing infant or milk production. The decision to breastfeed while using this medication should involve a discussion with a healthcare professional to weigh the benefits of breastfeeding against the mother's clinical need for the drug and any potential risks to the infant.

Q: What forms and strengths does Amvuttra come in?

Dosage Forms Amvuttra is supplied as a sterile, preservative-free solution for subcutaneous injection. It comes in the following form: Prefilled Syringe: A single-dose delivery system containing the medication as a clear, colorless-to-yellow liquid.

Q: What is the FDA approval status of Amvuttra?

FDA Approval Status Amvuttra (vutrisiran) was approved by the U.S. Food and Drug Administration (FDA) on June 13, 2022. It is manufactured by Alnylam Pharmaceuticals, Inc. and is classified as a transthyretin-directed small interfering RNA (siRNA) therapeutic. Approved Indications The FDA has approved Amvuttra specifically for the treatment of the polyneuropathy (nerve damage) associated with hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients. This condition is a rare, progressive genetic disorder that causes abnormal protein deposits to build up in the body's tissues. Regulatory Warnings and Requirements At the time of approval, the FDA did not require a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) for Amvuttra. However, the medication is known to lower serum vitamin A levels. Consequently, the FDA-approved labeling includes a requirement for healthcare providers to advise patients to take daily vitamin A supplements while on the medication. There have been no major safety communications or recalls reported for this drug since its initial approval.

Question 1

What is Amvuttra?

Accepted Answer

Amvuttra belongs to a class of medications known as RNA interference (RNAi) therapeutics. It works by targeting and breaking down the specific messenger RNA needed to produce the transthyretin protein in the liver.

By interfering with this genetic process, the medication lowers the levels of transthyretin protein circulating in the blood. This reduction is the primary mechanism by which the therapy functions within the body.

Question 2

What is Amvuttra used for?

Accepted Answer

Amvuttra is used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Question 3

How does Amvuttra work?

Accepted Answer

Mechanism of Action

Amvuttra is a type of medicine called a small interfering ribonucleic acid (siRNA). It is designed to target and reduce the levels of a protein called transthyretin (TTR), which is mostly produced in the liver.

In patients with hereditary transthyretin-mediated (hATTR) amyloidosis, the body produces abnormal TTR proteins. These proteins can misfold and stick together, forming deposits known as amyloid. These deposits build up in various parts of the body, including the nerves, leading to symptoms like numbness, pain, and weakness (polyneuropathy).

How it Works in the Body

Amvuttra works through a biological process called RNA interference. It identifies and breaks down the messenger RNA (mRNA) that provides the instructions for making the TTR protein. By blocking these instructions, the medication significantly lowers the amount of TTR protein released into the blood.

By decreasing the levels of this protein, Amvuttra helps to:

Limit the further buildup of amyloid deposits in the tissues.
Slow the progression of nerve damage associated with the condition.

Question 4

What are the active ingredients in Amvuttra?

Accepted Answer

The active ingredient in Amvuttra is vutrisiran.

Question 5

What are the side effects of Amvuttra?

Accepted Answer

Common side effects of Amvuttra may include:

injection site reactions
arthralgia
nausea

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Amvuttra?

Accepted Answer

Amvuttra belongs to the RNA interference therapeutic drug class.

Question 7

What is the dosage of Amvuttra and how do I take it?

Accepted Answer

Administration

Amvuttra is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. A healthcare professional will perform the injection in a clinical setting.

Common injection sites include:

The abdomen
The thighs
The back of the upper arms

Dosing Schedule

This medication is typically scheduled for administration once every three months. It is important to keep all scheduled appointments to ensure the medication works effectively.

Missed Doses

If a dose is missed, the injection should be administered by a healthcare professional as soon as possible. After receiving the missed dose, the next injection should be scheduled for three months after that date to maintain the regular quarterly cycle.

Vitamin A Supplementation

Because this medication can lower the levels of vitamin A in the blood, healthcare providers generally recommend taking a daily vitamin A supplement while receiving treatment. Patients should follow their provider's specific instructions regarding the amount and type of supplement to use.

Question 8

Is Amvuttra safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate and well-controlled studies of Amvuttra in pregnant individuals. Because the medication reduces the levels of transthyretin protein in the blood, it also leads to a significant decrease in serum vitamin A levels. Vitamin A is necessary for the normal development of a fetus.

In animal studies, vutrisiran showed evidence of developmental toxicity when administered at doses that were also toxic to the mother. While patients taking Amvuttra are typically advised to take vitamin A supplements, both vitamin A deficiency and excessive vitamin A intake can be harmful during pregnancy. Individuals who are pregnant or planning to become pregnant should discuss the potential risks and benefits of treatment with their healthcare provider.

Breastfeeding

It is not known if Amvuttra is present in human breast milk, nor is it known how the drug might affect a nursing infant or milk production. The decision to breastfeed while using this medication should involve a discussion with a healthcare professional to weigh the benefits of breastfeeding against the mother's clinical need for the drug and any potential risks to the infant.

Question 9

What forms and strengths does Amvuttra come in?

Accepted Answer

Dosage Forms

Amvuttra is supplied as a sterile, preservative-free solution for subcutaneous injection. It comes in the following form:

Prefilled Syringe: A single-dose delivery system containing the medication as a clear, colorless-to-yellow liquid.

Question 10

What is the FDA approval status of Amvuttra?

Accepted Answer

FDA Approval Status

Amvuttra (vutrisiran) was approved by the U.S. Food and Drug Administration (FDA) on June 13, 2022. It is manufactured by Alnylam Pharmaceuticals, Inc. and is classified as a transthyretin-directed small interfering RNA (siRNA) therapeutic.

Approved Indications

The FDA has approved Amvuttra specifically for the treatment of the polyneuropathy (nerve damage) associated with hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients. This condition is a rare, progressive genetic disorder that causes abnormal protein deposits to build up in the body's tissues.

Regulatory Warnings and Requirements

At the time of approval, the FDA did not require a Boxed Warning or a Risk Evaluation and Mitigation Strategy (REMS) for Amvuttra. However, the medication is known to lower serum vitamin A levels. Consequently, the FDA-approved labeling includes a requirement for healthcare providers to advise patients to take daily vitamin A supplements while on the medication. There have been no major safety communications or recalls reported for this drug since its initial approval.

Question 11

What should I know about Amvuttra and cost?

Accepted Answer

Insurance and Out-of-Pocket Costs

The price you pay for Amvuttra can vary significantly based on your insurance plan. Because this medication is administered by a healthcare professional, it is often covered under medical benefits (such as Medicare Part B) rather than a standard retail prescription drug plan. Your specific out-of-pocket costs will depend on your deductible, copay, or coinsurance requirements.

Specialty Pharmacy and Administration

Amvuttra is a specialty medication. It is not usually available at local retail pharmacies and must be ordered through a specialty pharmacy. In addition to the cost of the drug itself, you may be responsible for costs related to the healthcare provider's service for administering the subcutaneous injection every three months.

Financial Support Programs

Financial assistance may be available for those who qualify. The manufacturer often provides support services to help patients navigate insurance coverage and identify potential savings through copay cards or patient assistance programs. These programs are typically designed for individuals with commercial insurance or those who are uninsured or underinsured. It is recommended to contact your insurance provider or the manufacturer's patient support program to get a precise estimate of your costs.

Amvuttra

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Amvuttra

Hospitals.net Disclosure